FDA Approves Novartis’ New IL-17A-Blocking Psoriasis Drug Cosentyx
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.
Tag: Novartis
All
LatestSorry, No Posts Found
All
Latest
FDA Clears Expanded Indications for Swift Microwave Wart Device
New data show the Swift system reduces blistering, discomfort, and recovery time while maintaining strong clinical outcomes for common and plantar warts.
